Literature DB >> 422628

Biochemical disturbances associated with total hip replacement.

J P Alexander, D W Barron.   

Abstract

A prospective study on 227 patients undergoing arthroplasty of the hip was carried out with reference to the effects on the cardiovascular and respiratory systems. Investigations revealed that the placing of acrylic bone cement and the prosthesis in the femoral shaft produced clinical and biochemical disturbances which were consistent with pulmonary microembolism. A fall in arterial oxygen tension during the procedure and hypoxaemia extending into the postoperative period with elevation of serum lipase and a fall in triglycerides supported the idea that embolisation with marrow fat occurred. The method of venting (by catheter or proximal hole) did not influence the biochemical disturbances. The implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 422628

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  5 in total

1.  Non-cemented hip prostheses.

Authors:  J Nixon
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-08

2.  The uncemented Bicontact total hip arthroplasty in octogenarians. Medium-term results.

Authors:  N P Badhe; R C Quinnell; P W Howard
Journal:  Eur J Orthop Surg Traumatol       Date:  2002-12-18

3.  Effects of a distal venting hole in the femur during total hip replacement.

Authors:  L B Engesaeter; T Strand; T S Raugstad; S Husebø; N Langeland
Journal:  Arch Orthop Trauma Surg       Date:  1984

4.  Venting during prophylactic nailing for femoral metastases: current orthopedic practice.

Authors:  Dustin Dalgorf; Cornelia M Borkhoff; David J G Stephen; Joel Finkelstein; Hans J Kreder
Journal:  Can J Surg       Date:  2003-12       Impact factor: 2.089

5.  Venous thromboembolic disease in uncemented total hip replacement surgery--a one-year follow-up of 490 patients.

Authors:  P H Wittmann; F W Wittmann; P A Ring
Journal:  J R Soc Med       Date:  1991-09       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.